Drug Trial Radar · NCT04680598
Comparison of HBV Reactivation Between Patients With High HBV-DNA and Low HBV-DNA Loads Undergoing ICI and Concurrent Antiviral Prophylaxis: a Prospective Observational Study
Last checked: Nov 19, 2026Latest source record: Aug 2, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
800
Planned (sponsor's estimate)
Start
Dec 25, 2020
Primary completion
Dec 31, 2023
Study completion Dec 31, 2023
Sponsor
- Lead sponsor
- Sun Yat-sen UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Kaiping Central Hospital; Guangzhou No.12 People's Hospital; ZhongShan People 's Hospital
- First posted
- Dec 23, 2020
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
Summary
As written by the sponsor on the registry.
Immune checkpoint inhibitor (ICI), including programmed cell death protein-1 (PD-1) inhibitor or programmed cell death-Ligand 1 (PD-L1) inhibitor , is recommended to treat advanced hepatocellular carcinoma (HCC). However, the safety of ICI in patients with a high HBV-DNA load is unknown because of the potential risk of hepatitis B virus (HBV) reactivation. This study was to compare the HBV reactivation between patients with low HBV-DNA loads and high HBV-DNA loads undergoing antiviral prophylaxis and ICI.
Conditions
- Hepatocellular Carcinoma
Interventions
ICIDrug
Patients received ICI, including PD-1 inhibitor (pembrolizumab, toripalimab, nivolumab, sintilimab, camrelizumab) or PD-L1 inhibitor (atezolizumab)
Antiviral ProphylaxisDrug
Patient received concurrent antiviral prophylaxis, such as tenofovir, entecavir
Primary outcomes
What the sponsor says the trial is designed to measure.
- HBV Reactivation rateTime frame: 2 months
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
ZhongShan People 's Hospital
Zhongshan, China · Recruiting
Cancer Center Sun Yat-sen University
Guangzhou, Guangdong, China · Recruiting
Guangzhou Twelfth People 's Hospital
Guangzhou, Guangdong, China · Recruiting
Kaiping Central Hospital
Kaiping, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.